At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SNDX Syndax Pharmaceuticals
Trading 08-11 10:32:36 EDT
20.20
-0.17
-0.83%
High20.58Low19.93Vol222.26K
Open20.46D1 Closing20.37Amplitude3.17%
Mkt Cap1.80BTradable Cap1.61BTotal Shares89.30M
T/O4.50MT/O Rate0.28%Tradable Shares79.57M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Syndax Pharmaceuticals (SNDX) Stock Looks Stretched As Its 63% Run Continues
Simply Wall St.  ·  08-09 14:40
Syndax Pharmaceuticals (SNDX) Stock Looks Stretched As Its 63% Run Continues
U.S. Stocks Decline Midday Thursday as Traders Monitor Iran Tensions, Sandisk Drops 5%
Deep News  ·  08-07
U.S. Stocks Decline Midday Thursday as Traders Monitor Iran Tensions, Sandisk Drops 5%
Nuvation Bio Q2 Revenue Beats Estimates on Ibtrozi Growth
Reuters  ·  08-06
Nuvation Bio Q2 Revenue Beats Estimates on Ibtrozi Growth
Syndax Grants Stock Option Awards for 59,250 Shares to Five New Employees
Reuters  ·  08-06
Syndax Grants Stock Option Awards for 59,250 Shares to Five New Employees
Arcutis Q2 Revenue Rises on Demand for Zoryve, Lifts 2026 Sales Outlook
Reuters  ·  08-06
Arcutis Q2 Revenue Rises on Demand for Zoryve, Lifts 2026 Sales Outlook
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire  ·  08-06
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
UroGen Pharma Q2 Revenue Beats on Strong Zusduri Sales
Reuters  ·  08-05
UroGen Pharma Q2 Revenue Beats on Strong Zusduri Sales
Syndax Pharmaceuticals, Inc. : Bofa Global Research Cuts Price Objective to $26 from $29
THOMSON REUTERS  ·  08-05
Syndax Pharmaceuticals, Inc. : Bofa Global Research Cuts Price Objective to $26 from $29
Analysts Offer Insights on Healthcare Companies: TG Therapeutics (TGTX), Syndax Pharmaceuticals (SNDX) and DaVita (DVA)
TIPRANKS  ·  08-05
Analysts Offer Insights on Healthcare Companies: TG Therapeutics (TGTX), Syndax Pharmaceuticals (SNDX) and DaVita (DVA)
Geron's Q2 Revenue Rises on Rytelo Growth
Reuters  ·  08-05
Geron's Q2 Revenue Rises on Rytelo Growth
Even Big Profits Aren't Enough to Keep Chip Investors Happy
Dow Jones  ·  08-05
Even Big Profits Aren't Enough to Keep Chip Investors Happy
Syndax Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-05
Syndax Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Syndax 1H FY26 Net Loss Narrows to $49.4 Million; 2Q FY26 Revenue Rises 92% to $72.8 Million
Reuters  ·  08-05
Syndax 1H FY26 Net Loss Narrows to $49.4 Million; 2Q FY26 Revenue Rises 92% to $72.8 Million
Syndax Q2 Revenue Jumps 92% on Revuforj, Niktimvo Demand
Reuters  ·  08-05
Syndax Q2 Revenue Jumps 92% on Revuforj, Niktimvo Demand
Syndax Pharmaceuticals Q2 EPS $(0.55) Misses $(0.49) Estimate, Sales $72.788M Miss $79.323M Estimate
Benzinga Earnings  ·  08-05
Syndax Pharmaceuticals Q2 EPS $(0.55) Misses $(0.49) Estimate, Sales $72.788M Miss $79.323M Estimate
Syndax Pharmaceuticals Q2 Operating Income USD -39.995 Million
Reuters  ·  08-05
Syndax Pharmaceuticals Q2 Operating Income USD -39.995 Million
US Market Movers: Amazon Surges Over 15% on Strong Cloud Results, Apple Drops 7% on Component Constraints
Deep News  ·  08-01
US Market Movers: Amazon Surges Over 15% on Strong Cloud Results, Apple Drops 7% on Component Constraints
AI Stocks May Have Bottomed Out. What Investors Should Watch for Next.
Dow Jones  ·  08-01
AI Stocks May Have Bottomed Out. What Investors Should Watch for Next.
Earning Preview: Syndax Pharmaceuticals Q2 revenue is expected to increase by 195.71%, and institutional views are bullish
Earnings Agent  ·  07-29
Earning Preview: Syndax Pharmaceuticals Q2 revenue is expected to increase by 195.71%, and institutional views are bullish
Apple market value reaches $5 trillion for the first time, Micron plunges on Tuesday trading
Deep News  ·  07-29
Apple market value reaches $5 trillion for the first time, Micron plunges on Tuesday trading

Introduction

Company Name.
Syndax Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
Issue price:
--